Antidogmatic approaches to artemisinin resistance: Reappraisal as treatment failure with artemisinin combination therapy

Trends in Parasitology

Volumn 29, Issue 7, 2013, Pages 313-317

  Krishna, Sanjeev ^a,b,c   Kremsner, Peter Gottfried ^b,c  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c Centre de Recherches Médicales de Lambaréné HÔpital Albert Schweitzer   (Gabon)

Author keywords

Antimalarial; Artemisinin; Atovaquone; Dormancy; Drug resistance; Malaria; Parasite clearance; Plasmodium falciparum

Indexed keywords

ARTEMISININ; ARTESUNATE; ARTESUNATE PLUS MEFLOQUINE; PIPERAQUINE;

ANTIMALARIAL DRUG RESISTANCE; ASSAY; DRUG TREATMENT FAILURE; GENOTYPE; HOST; HUMAN; IN VITRO STUDY; MALARIA; MONOTHERAPY; NONHUMAN; PARASITE CLEARANCE; PARASITEMIA; PHENOTYPE; REVIEW; RISK ASSESSMENT; TREATMENT FAILURE OF ARTEMISININ COMBINATION THERAPY;

ANIMALS; ANTIMALARIALS; ARTEMISININS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; TREATMENT FAILURE;

PLASMODIUM FALCIPARUM;

EID: 84879461292     PISSN: 14714922     EISSN: 14715007     Source Type: Journal    
DOI: 10.1016/j.pt.2013.04.001     Document Type: Review

References (37)

1. Kremsner P.G., Krishna S. Antimalarial combinations. Lancet 2004, 364:285-294.
2. Shretta R., Yadav P. Stabilizing supply of artemisinin and artemisinin-based combination therapy in an era of wide-spread scale-up. Malar. J. 2012, 11:399.
3. Dondorp A.M., et al. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 2009, 361:455-467.
4. Amaratunga C., et al. Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect. Dis. 2012, 12:851-858.
5. Phyo A.P., et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet 2012, 379:1960-1966.
6. Cheeseman I.H., et al. A major genome region underlying artemisinin resistance in malaria. Science 2012, 336:79-82.
7. White N.J. Counter perspective: artemisinin resistance: facts, fears, and fables. Am. Soc. Trop. Med. Hyg. 2012, 87:785.
8. Fairhurst R.M., et al. Artemisinin-resistant malaria: research challenges, opportunities, and public health implications. Am. Soc. Trop. Med. Hyg. 2012, 87:231-241.
9. Meshnick S. Perspective: artemisinin-resistant malaria and the wolf. Am. Soc. Trop. Med. Hyg. 2012, 87:783-784.
10. O'Brien C., et al. Recent clinical and molecular insights into emerging artemisinin resistance in Plasmodium falciparum. Curr. Opin. Infect. Dis. 2011, 24:570-577.
11. Kessl J.J., et al. Modeling the molecular basis of atovaquone resistance in parasites and pathogenic fungi. Trends Parasitol. 2007, 23:494-501.
12. Painter H.J., et al. Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum. Nature 2007, 446:88-91.
13. Musset L., et al. Clinical atovaquone-proguanil resistance of Plasmodium falciparum associated with cytochrome b codon 268 mutations. Microbes Infect. 2006, 8:2599-2604.
14. Nixon G.L., et al. Antimalarial pharmacology and therapeutics of atovaquone. J. Antimicrob. Chemother. 2013, 68:977-985.
15. Borrmann S., et al. Short-course artesunate treatment of uncomplicated Plasmodium falciparum malaria in Gabon. Antimicrob. Agents Chemother. 2003, 47:901-904.
16. Kyaw M.P., et al. Reduced susceptibility of Plasmodium falciparum to artesunate in Southern Myanmar. PLoS ONE 2013, 8:e57689.
17. Noedl H., et al. Evidence of artemisinin-resistant malaria in western Cambodia. N. Engl. J. Med. 2008, 359:2619-2620.
18. Saunders D., et al. Pharmacokinetics and pharmacodynamics of oral artesunate monotherapy in patients with uncomplicated Plasmodium falciparum malaria in western Cambodia. Antimicrob. Agents Chemother. 2012, 56:5484-5493.
19. Price R.N., et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 2004, 364:438-447.
20. Price R.N., et al. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin. Infect. Dis. 2006, 42:1570-1577.
21. Carrara V.I., et al. Malaria burden and artemisinin resistance in the mobile and migrant population on the Thai-Myanmar border, 1999-2011: an observational study. PLoS Med. 2013, 10:e1001398.
22. Pulcini, S. et al. Expression in yeast links field polymorphisms in PfATP6 to in vitro artemisinin resistance and identifies new inhibitor classes. J. Infect. Dis. (in press).
23. Angus B.J., et al. In vivo removal of malaria parasites from red blood cells without their destruction in acute falciparum malaria. Blood 1997, 90:2037-2040.
24. Buffet P.A., et al. The pathogenesis of Plasmodium falciparum malaria in humans: insights from splenic physiology. Blood 2011, 117:381-392.
25. Chotivanich K., et al. Central role of the spleen in malaria parasite clearance. J. Infect. Dis. 2002, 185:1538-1541.
26. Huang S., et al. Dynamic deformability of Plasmodium falciparum-infected erythrocytes exposed to artesunate in vitro. Integr. Biol. (Camb.) 2013, 5:414-422.
27. Piedade R., Gil J.P. The pharmacogenetics of antimalaria artemisinin combination therapy. Expert Opin. Drug Metab. Toxicol. 2011, 7:1185-1200.
28. ter Kuile F.O., et al. Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of antimalarials used for the treatment of severe malaria. Exp. Parasitol. 1993, 76:85-95.
29. Wilson D.W., et al. Defining the timing of action of anti-malarial drugs against Plasmodium falciparum. Antimicrob. Agents Chemother. 2013, 57:1455-1467.
30. Kremsner P.G., et al. A simplified intravenous artesunate regimen for severe malaria. J. Infect. Dis. 2012, 205:312-319.
31. Saralamba S., et al. Intrahost modeling of artemisinin resistance in Plasmodium falciparum. Proc. Natl. Acad. Sci. U.S.A. 2010, 108:397-402.
32. Teuscher F., et al. Artemisinin-induced dormancy in Plasmodium falciparum: duration, recovery rates, and implications in treatment failure. J. Infect. Dis. 2010, 202:1362-1368.
33. Codd A., et al. Artemisinin-induced parasite dormancy: a plausible mechanism for treatment failure. Malar. J. 2011, 10:56.
34. Menard D., et al. Association of failures of seven-day courses of artesunate in a non-immune population in Bangui, Central African Republic with decreased sensitivity of Plasmodium falciparum. Am. J. Trop. Med. Hyg. 2005, 73:616-621.
35. Bethell D., et al. Dose-dependent risk of neutropenia after 7-day courses of artesunate monotherapy in Cambodian patients with acute Plasmodium falciparum malaria. Clin. Infect. Dis. 2010, 51:e105-e114.
36. Valderramos S.G., et al. Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance. Antimicrob. Agents Chemother. 2010, 54:3842-3852.
37. Hayward R., et al. pfmdr1 mutations associated with chloroquine resistance incur a fitness cost in Plasmodium falciparum. Mol. Microbiol. 2005, 55:1285-1295.